Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published Date April 2008 Volume 2008:4(2) Pages 337—344

DOI http://dx.doi.org/10.2147/TCRM.S1209

Published 21 April 2008

Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Clinical issues of mucus accumulation in COPD

Osadnik CR, McDonald CF, Holland AE

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:301-302

Published Date: 25 March 2014

Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]

Bosani M, Ardizzone S, Porro GB

Biologics: Targets and Therapy 2014, 8:39-40

Published Date: 31 January 2014

Causal diagrams and the logic of matched case-control studies [Corrigendum]

Shahar E, Shahar DJ

Clinical Epidemiology 2014, 6:59-60

Published Date: 22 January 2014

Targeting nanomaterials: future drugs for cancer chemotherapy

Zhang Y, Chen T

International Journal of Nanomedicine 2012, 7:5283-5286

Published Date: 10 October 2012

Corrigendum

Brief G, Lammich T, Nagel E, Pfennigsdorf S, Spraul CW, Ho S

Clinical Ophthalmology 2012, 6:1271-1272

Published Date: 6 August 2012

Corrigendum

Jalil MA, Moongfangklang M, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:3279-3280

Published Date: 29 June 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 17 November 2008